Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drugCNBC • 03/10/25
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 03/09/25
ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVOAccesswire • 03/09/25
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join – Contact Levi & KorsinskyAccesswire • 03/08/25
ROSEN, A LEADING AND RANKED FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVOAccesswire • 03/08/25
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVOGlobeNewsWire • 03/07/25
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 03/07/25
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVOGlobeNewsWire • 03/07/25
ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVOAccesswire • 03/06/25
The Gross Law Firm Reminds Novo Nordisk A/S Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 – NVOGlobeNewsWire • 03/06/25
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%Zacks Investment Research • 03/06/25
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Novo Nordisk A/S Investors with Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 03/06/25
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVOAccesswire • 03/06/25
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens BermanAccesswire • 03/06/25
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of PocketInvestopedia • 03/05/25
Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival's moveNew York Post • 03/05/25
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?Zacks Investment Research • 03/05/25